HSA's September 25 warning separates experimental injectables from approved prescription medicines obtained without medical oversight.
Why it matters
An online seller's research label does not establish suitability for human use.
What we don't know
The notice supplies no case counts or risk denominator. It is not a recall, a topical peptide skincare assessment, or evidence that every peptide has the same risks.
Two different situations
HSA describes serious reactions reported after purchases through unauthorised channels. It distinguishes prescription GLP-1 medicines used without supervision from experimental injectable peptides, naming retatrutide and cagrilintide as unapproved in its dated warning.
The agency flags uncertain contents and quality, and advises obtaining prescribed products from established pharmacies, hospitals or clinics with a doctor's assessment. Do not read this as advice to stop prescribed treatment.
Keep the evidence in scope
Grade A describes the documented Singapore advisory, not peptide efficacy or a measured complication rate. This is a regulator communication, not a commercially sponsored treatment trial. Source checked September 26, 2026.
Open the source file
These links support the claims above. Source dates, disclosures and limits are documented in the article and source list.